November 17, 2011 — Westside Medical Imaging of Beverly Hills announces the availability of high resolution magnetic resonance imaging (MRI) with a 3 Tesla magnet to monitor the effects of cholesterol drugs on atherosclerosis.

Norman Lepor, M.D., Hooman Madyoon, M.D., and Michael Duffy, M.D., of Westside Medical Associates of Los Angeles (WMALA) have adopted 3 Tesla MRI using specialized vascular coils to monitor cholesterol drug performance; they do this by following carotid plaque volume and morphology.

According to Lepor, who has reviewed this issue for the upcoming edition of Reviews in Cardiovascular Medicine, "MRI of plaques with a 3 Tesla magnet represents a pivotal development in vascular medicine. It enhances our capability to identify atherosclerotic plaques with a greater degree of sensitivity then carotid intima-media thickness (cIMT) and follow the effects of medical treatments with more accuracy."

Binh Phan, M.D., co-author of this study, found intensive treatment with cholesterol drugs reduced the amount of cholesterol in artery-clogging plaque in 120 patients randomly assigned to receive one of three cholesterol treatments: Lipitor; Lipitor plus Niaspan; or Lipitor plus Niaspan and colesevelam. After three years, the volume of cholesterol decreased from 60.4 cubic mm2 to 37.4 mm2. The percentage of plaque volume consisting of cholesterol decreased from 14.2 percent to 7.4 percent.

According to Madyoon, "because atherosclerosis occurs in blood vessels throughout the body, plaque build-up in carotid arteries is a good surrogate marker for build-up in the coronary arteries indicating a higher risk of heart attack and stroke."

Men over the age of 40 and women approaching menopause with a history of hypertension, elevated cholesterol, diabetes, smoking history or family history of heart disease should consider this exam.

These findings confirmed the theory that cholesterol medications lead to plaque regression by lowering cholesterol levels. According to Lepor, "this MRI technology will also allow physicians to individualize cholesterol therapy rather then treat everyone the same."

According to Duffy, "one of the key advantages of this technology is that you can assess the carotid arteries for plaque progression or regression serially over time since it does not expose the patient to any ionizing radiation."

For more information: www.westsidemedimaging.com


Related Content

News | Radiology Imaging

April 20, 2026 — Bracco Imaging has announced a strategic alliance with NYU Langone Health to advance innovation in ...

Time April 23, 2026
arrow
News | Radiology Imaging

April 7, 2026 — Onvida Health and Siemens Healthineers have entered a 10-year Value Partnership¹ designed to bring the ...

Time April 09, 2026
arrow
News | SNMMI

The Society of Nuclear Medicine and Molecular Imaging's (SNMMI) 2026 Annual Meeting will take place May 30–June 2 in Los ...

Time April 07, 2026
arrow
News | Radiology Business

March 31, 2026 — Radon Medical Imaging, a medical imaging equipment maintenance and repair services company, has has ...

Time March 31, 2026
arrow
News | Radiology Imaging

March 26, 2026 — GE HealthCare has announced a renewed research collaboration with Stanford Medicine Department of ...

Time March 30, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

March 25, 2026 A Penn Medicine–led team has developed a first‑of‑its‑kind artificial intelligence system that interprets ...

Time March 26, 2026
arrow
News | Radiology Education

March 17, 2026 – The Center for Radiology Education (CRE) has announced a nationwide initiative to provide scholarships* ...

Time March 17, 2026
arrow
News | Radiology Business

March 12, 2026 — DelveInsight's has released its latest Diagnostic Imaging Equipment Market Insights report. The in ...

Time March 13, 2026
arrow
Feature | Artificial Intelligence | Kyle Hardner

Once considered an adjunct brain cancer therapy and a last-resort treatment, noninvasive radiosurgery has evolved ...

Time March 09, 2026
arrow
News | Artificial Intelligence

March 2, 2026 — RadNet, Inc. has acquired Gleamer SAS, a radiology AI company based in Paris, France. Gleamer will be ...

Time March 03, 2026
arrow
Subscribe Now